West Pharmaceutical Services (WST) reported strong Q4 2025 earnings, exceeding revenue and EPS expectations. The company posted an EPS of $2.04 against a forecast of $1.84, and revenue of $805 million compared to an anticipated $796.25 million, leading to a 4.07% rise in pre-market stock price. Key drivers include high-value product components, expansion in the GLP-1 market, and upgrades related to Annex 1 regulations.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations
West Pharmaceutical Services (WST) reported strong Q4 2025 earnings, exceeding revenue and EPS expectations. The company posted an EPS of $2.04 against a forecast of $1.84, and revenue of $805 million compared to an anticipated $796.25 million, leading to a 4.07% rise in pre-market stock price. Key drivers include high-value product components, expansion in the GLP-1 market, and upgrades related to Annex 1 regulations.